Viral hepatitis

Dr. Abdulkarim Alhetheel and Dr. Malak Elhazmi

Assistant Professor

College of Medicine & KKUH

Hepatitis

• Is inflammation of the liver.

Etiology

- □ Primary infection:
- Hepatitis A virus (HAV)
- ➢ Hepatitis B virus (HBV).
- > Hepatitis C virus (HCV), was known as non-A non-B hepatitis,
- > Hepatitis D virus (HDV) or delta virus.
- ➢ Hepatitis E virus (HEV).
- ≻ Hepatitis F virus (HFV).
- ➢ Hepatitis G virus (HGV).

As part of generalized infection:
 (CMV, EBV, Yellow fever virus)

Continued


- Hepatitis F has been reported in the literature but not confirmed.
- Viral hepatitis is divided into two large groups, based on the mode of transmission:
- 1– Enterically transmitted hepatitis or water-borne hepatitis. This group includes hepatitis A and E viruses.

2– Parenterally transmitted hepatitis or blood-borne hepatitis. This group includes hepatitis B, C, D & G viruses.

Characteristics of HAV

Family of *Picornaviridae*.Genus: *Hepatovirus*.Virion non-enveloped and consist of:

- Icosahedral capsid.
- Positive sense ss-RNA.
- Short incubation hepatitis
- Infectious hepatitis
- Epidemic hepatitis



Geographic Distribution of HAV Infection



Epidemiology



Distribution:

Worldwide, endemic in tropical countries
 Transmission:


 Faecal-oral route [major route]
 Contaminated food &water
 Sexual contact (homosexual men)
 Blood transfusion (very rarely)

Age:

In developing countries; childrenIn developed countries; young adults








- The virus enters the body by ingestion of contaminated food. It replicates in the intestine, and then spread to the liver where it multiplies in hepatocytes.
- CMI
 Damage of virus-infected hepatocytes
 ALT, AST & Bilirubin





Manifestations



4 Hepatitis

- Asymptomatic & anicteric inf _____ common
- Symptomatic illness ———
- **4** IP=2-6 Ws
- Pre-icteric phase: fever, fatique, N, V, & RUQP (right upper quadrant pain)

age

44 Icteric phase: dark urine, pale stool, jaundice





Prognosis



- Self-limited disease
- **4** Fulminant hepatitis rare
- **4** Mortality rate ~ 0.1 0.3%
- No chronicity or malignancy changes

Lab Diagnosis



Serology: Detection of anti-HAV IgM Current infection Detection of Anti-HAV IgG Previous infection Immunity





4 Treatment:


- Supportive therapy
- Prevention:
 - Sanitation & hygiene measures
 - Hig: Given before or within 2 Ws of exposure
 - Indication: travellers, unvaccinated, exposed patients.
 - Vaccine: inactivated (killed)
 - Given IM in two doses
 - >1 Y of age
 - Indication: Patients at high risk of infection and severe disease

Characteristics of HEV

Family of *Hepeviridae*. Genus: *Hepevirus*.

Virion non-enveloped and consist of:

- Icosahedral capsid.
- Positive sense ss-RNA.



HEPATITIS E VIRUS

- **4** Epidemiology:
- 4 Outbreak of water-borne & sporadic cases of VH
- **Age**; young adults
- **4** routes of transmission;
 - **4** Water-borne
 - **4** Zoonotic food-borne
 - **4** Blood-borne
 - 4 Perinatal

HEPATITIS E VIRUS

- **4** Clinical features:
 - Similar to HAV infection with exceptions:
 Longer IP =4-8 Ws
 Chronic hepatitis, cirrhosis, but not HCC.
 Fulminant disease
 Mortality rate ~10 times > HAV ~ 1-3% [20% in pregnancy]

HEPATITIS E VIRUS

Lab diagnosis:
ELISA Anti-HE IgM
Treatment:
Not specific
Prevention:
Sanitation & hygiene measures
No Immunoglobulin
No vaccine

Herpesviridae

1-Herpes simplex virus type -1	HSV-1	
2-Herpes simplex virus type -2	HSV-2	
3-Varicella –Zoster virus	VZV	H
4-Epstein-Barr virus	EBV	
5-Cytomegalovirus	CMV	
6-Human herpes virus type-6	HHV-6	
7-Human herpes virus type-7	HHV-7	
8-Human herpes virus type-8	HHV-8	

dsDNA, Icosahedral & Enveloped Virus

<u> Epstein – Barr Virus_EBV</u>



It is lymphotropic.

It has oncogenic properties; Burkitt's lymphoma

Nasopharyngeal carcinoma

Epidemiology

- Distribution: worldwide igodol
- Transmission: lacksquare
 - Saliva [kissing disease]
 - Blood [rarely]
- Age: \bullet

Socio-economic status: SE

- Low SE class early childhood
- High SE class



adolescence



<u>1-Immunocompetent host</u>

• Asymptomatic

•

•

- Infectious mononucleosis [or glandular fever]
 - Mainly in teenagers & young adults
 - \blacktriangleright IP = 4-7 weeks
 - Fever, pharyngitis, malaise, hepatosplenomegaly & abnormal LFT, hepatitis.
 - Complications

(acute air way obstruction, splenic rupture, CNS inf)

Chronic EBV infection

<u>2-Immunocompromised host</u>

Lymphoproliferative disease (LD)
Oral hairy leukoplakia (OHL)




Diagnosis:



Hematology: WBC lymphocytosis


(Atypical lymphocytes)



Atypical lymphocyte with deformed nucleus and dark rimmed cytoplasm

Serology:

- Non-specific AB test ;
 - Heterophile Abs +ve
 - Paul-Bunnell or monospot test



EBV-specific AB test: IgM Abs to EBV capsid antigen







- Antiviral drug is not effective in IMN
- Prevention:
 - No vaccine

<u>Cytomegalovirus</u> CMV

- Special features;
- Its replication cycle is longer.
- Infected cell enlarged with multinucleated.
 [cyto=cell, megalo=big]
- Resistant to acyclovir.
- Latent in monocyte,
 lymphocyte & other.

- Distribution: worldwide
- Transmission;
- Early in life:
 - Transplacental
 - Birth canal
 - Breast milk
- Young children: saliva
- Later in life: sexual contact, Blood transfusion & organ transplant.



Acquired Infection;

- Immunocompetent host
 - Asymptomatic
 - Self-limited illness
 - Hepatitis
 - Infectious mononucleosis like syndrome
 [Heterophile AB is -ve]
- Immunocompromised host
 - Encephalitis, Retinitis, Pneumonia,
 - Hepatitis, Esophagitis, Colitis.


Congenital Infections





Histology: Intranuclear inclusion bodies [Owl's eye]

- * Culture:
 - In human fibroblast
 - 1-4 wks 🔶 CPE
 - Shell Vial Assay → 1-3 days



- * Serology :
 - > AB
- IgM: current inf IgG: previous exposure CMV pp65 Ag by IFA





<u>Treatment:</u>

- Ganciclovir
 - is effective in the treatment of severe CMV inf.
- *Foscarnet:* the 2nd drug of choice .

Prevention:


Screening;


- Organ donors
- Organ recipients
- Blood donors
- Leukocyte-depleted blood.
- Prophylaxis: Ganciclovir, CMVIG.
- No vaccine.

<u>Arthropod – borne Viruses</u> (Arboviruses)

Yellow Fever virus

- Family: *Flaviviridae*
- Asymptomatic to Jaundice (hepatitis) + Fever ± hemorrhage ± renal failure
- Epidemiology
 Tropical Africa & South America
 1. Jungle Yellow Fever
 - 2. Urban Yellow Fever





Jungle Yellow Fever

- Vector: mosquito
- Reservoir: monkeys
- Accidental host: humans
- It is a disease of monkeys

<u>Urban Yellow Fever</u>

- Vector: mosquito
- Reservoir: human
- It is a disease of humans




- Reference Lab
- Lab Methods:
 - A- Isolation (Gold standard)
 - B IgM-Ab ELISA, IF: (most used)
 - C Arbovirus RNA by RT-PCR

Prevention:

- **1-Vector Control:**
- Elimination of vector breading sites
- Using insecticides
- Avoidance contact with vectors

2-Vaccines:

Yellow Fever vaccine (LAV, one dose /10 yrs) It is recommended for travelers.



Reference books &the relevant page numbers

<u>Medical Microbiology.</u>

By: David Greenwood ,Richard Slack, John Peutherer and Mike Barer.
17th Edition, 2007.
Pages; 428-435, 484-485, 507-523, 533-534.

Review of Medical Microbiology and

<u>Immunology.</u>

- By: Warren Levinson.
- 10th Edition, 2008.

Pages; 257-259, 292-294, 301, 305-306





REVIEW OF Medical Microbiology and Immunology

VARREN LEVINSON



Thank you for your attention !